SCHEMBL14032002

SCHEMBL14032002

COOSCCN(Cc1cccc(-c2nc3c(SC)ncnc3s2)c1)C(=O)OC(C)(C)C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 9/20 0.34
PPARG P37231 6/20 0.33
PAX8 Q06710 1/20 0.32
IKBKB O14920 1/20 0.32
CHUK O15111 1/20 0.32
CDK2 P24941 1/20 0.32
BTK Q06187 1/20 0.32
ITK Q08881 1/20 0.32
IKBKE Q14164 1/20 0.32
GLS O94925 1/20 0.31
LHCGR P22888 1/20 0.31
CYP2C9 P11712 2/20 0.31
KCNH2 Q12809 1/20 0.31
KDM4E B2RXH2 1/20 0.30
NPC1 O15118 1/20 0.30
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30
HTT P42858 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5061163 0.89 SSTR4 (0.37) PPARAPPARGPAX8IKBKBCHUK
SCHEMBL5064178 0.86 IKBKB (0.34) PPARAPAX8IKBKBCHUKCDK2
SCHEMBL5069029 0.82 PAX8 (0.34) PAX8
SCHEMBL5068866 0.80 PAX8 (0.34) PAX8CYP2C9KDM4ENPC1MAPT
SCHEMBL5068892 0.80 SSTR4 (0.40) PAX8CDK2HTT
SCHEMBL5064760 0.79 PAX8 (0.33) PAX8KDM4E
SCHEMBL5067502 0.76 IKBKB (0.38) PAX8IKBKBCHUKCDK2BTK
SCHEMBL5064698 0.70 PIK3CD (0.38) IKBKBCHUKCDK2BTKITK
SCHEMBL25737173 0.61 HDAC3 (0.51) LMNA
SCHEMBL30262616 0.61 HDAC1 (0.39) PPARAGLSHSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269238-A1 Thiazolopyrimidine Derivative FGFR3, FGFR1, ERBB3 PPARA 594/4885PPARG 461/4885PAX8 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.